

„Entdecke die Möglichkeiten“ Dauer der Antikoagulation nach venöser Thromboembolie Umgang mit Leitlinienempfehlungen in der Praxis

1. Interdisziplinäre S2k-Leitlinie Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Fassung vom 01.09.2015. AMWF online.
2. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores CL. Antithrombotic therapy for VTE disease. CHEST guideline and expert panel report. *Chest* 2016;149:315-352.
3. Interdisziplinäre S2-Leitlinie Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Fassung vom 01.06.2010. AMWF online.
4. Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Bernardi F, Coccheri S. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. *Circulation* 2003;108:313-318.
5. Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Iorio A. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. *Ann Intern Med* 2010;153:523-531.
6. Palareti G, Cosmi B, Legnani C, Antonucci E, De M, Ghirarduzzi VA, Poli D, Testa S, Tosetto A, Pengo V, Prandoni P. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. *Blood* 2014;124:196-203.
7. Kyrle PA & Eichinger S. Clinical scores to predict recurrence risk of venous thromboembolism. *Thromb Haemost* 2012;108:1061-1064.
8. Mearns ES, Coleman CI, Patel D, Saulsberry WJ, Corman A, Li D, Hernandez AV, Kohn CG., Index clinical manifestation of venous thromboembolism predicts early recurrence type and frequency: a meta-analysis of randomized controlled trials. *J Thromb Haemost* 2015;13:1043-1052.
9. Donadini MP, Ageno W, Antonucci E, Cosmi B, Kovacs MJ, Le GG, Ockelford P, Poli D, Prandoni P, Rodger M, Saccullo G, Siragusa S, Young L, Bonzini M, Caprioli M, Dentali F, Iorio A, Douketis JD. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. *Thromb Haemost* 2014;111:172-179.
10. Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, Kyrle P, Poli D, Tait RC, Iorio A. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. *BMJ* 2011;342:d813.
11. Bueller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med* 2012;366:1287-1297.
12. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. *N Engl J Med* 2013;368:709-718.
13. Agnelli G, Bueller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI. Apixaban for extended treatment of venous thromboembolism. *N Engl J Med* 2013;368:699-708.
14. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P. Aspirin for preventing the recurrence of venous thromboembolism. *N Engl J Med* 2012;366:1959-1967.
15. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J. Low-dose aspirin for preventing recurrent venous thromboembolism. *N Engl J Med* 2012;367:1979-1987.
16. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. *N Eng J Med* 2017;376:1211-1222.